The investigators will enroll 100 sexually active, meth-dependent MSM who will be randomized 1:1 to receive monthly injections of extended-release naltrexone (n=50) or placebo (n=50) for 12 weeks at weeks 0, 4, and 8. Study participants will be seen weekly at our site at the HIV Prevention Section of the San Francisco Department of Public Health, where they will provide urine for drug testing and participate in substance use counseling. All participants will receive HIV risk-reduction counseling. Behavior will be assessed using standardized measures via audio computer-assisted self-interview (ACASI).
Article source: http://clinicaltrials.gov/ct2/show/NCT01449565?term=hiv&lup_s=09%2F01%2F2012&lup_d=30
Related posts
- A Phase 2a Study of GS-6624 in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis
- 5th Street Games Launches 4th Game: My Happy Farm
- First up for Indiana legislature: Ban gay marriage
- Westtown School Robotics: The Formidable Metal Moose
- ESPN Audio and ESPN.com to Present Coverage of Legends of Football Discussion Panel During Super Bowl Weekend
- Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
- Italian Parliament Rejects Gay Rights Bill
- Ministers spreading HIV: Mugabe
- Gay Marriage Events Today/Tomorrow: LA, SF, NYC, Seattle
- Integrated Treatment for Smoking Cessation & Anxiety in People With HIV Phase 1
